Business
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nu...
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented
About this update from Jaguar Health, Inc.
[{"type":"text","content":"REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting \n Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37% SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today issued a reminder that an abstract describing partial results of the independent and ongoing investigator-initiated trial (IIT) of crofelemer in the UAE for treatment of pediatric intestinal failure, which includes patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), will be presented this coming Saturday, November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place November 5-8, 2025 in Chicago.The results of the ongoing investigator-initiated proof-of-concept trial in the UAE demonstrate reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) in pediatric intestinal failure patients ranging between 12% to 37%.MVID is a devastating ultrarare pediatric disorder, with an estimated worldwide prevalence of 100-200 patients, characterized by severe malabsorption that requires life-sustaining parenteral support to meet the nutritional, fluid and electrolyte requirements of the child, and for which there are currently no approved treatments. MVID has a lethal natural history along with significant co-morbidities. SBS affects approximately 10,000 to 20,000 people in the U.S., according to the Crohn's & Colitis Foundation, and it is estimated that the population of SBS patients in Europe is approximately the same size.\"We are very pleased with the initial findings from this pilot open-label study in pediatric intestinal failure patients with MVID and SBS. The unique mechanism of action of crofelemer and the reductions achieved in the average weekly...